Heron Therapeutics (HRTX) Return on Equity (2016 - 2025)
Historic Return on Equity for Heron Therapeutics (HRTX) over the last 13 years, with Q3 2025 value amounting to 0.26%.
- Heron Therapeutics' Return on Equity fell 9200.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year decrease of 9200.0%. This contributed to the annual value of 0.41% for FY2024, which is 104800.0% down from last year.
- According to the latest figures from Q3 2025, Heron Therapeutics' Return on Equity is 0.26%, which was down 9200.0% from 0.04% recorded in Q2 2025.
- Over the past 5 years, Heron Therapeutics' Return on Equity peaked at 5.43% during Q2 2023, and registered a low of 582.18% during Q3 2022.
- In the last 5 years, Heron Therapeutics' Return on Equity had a median value of 0.26% in 2025 and averaged 48.24%.
- Its Return on Equity has fluctuated over the past 5 years, first crashed by -5805700bps in 2022, then soared by 5857900bps in 2023.
- Over the past 5 years, Heron Therapeutics' Return on Equity (Quarter) stood at 2.22% in 2021, then crashed by -337bps to 9.7% in 2022, then surged by 137bps to 3.58% in 2023, then plummeted by -91bps to 0.31% in 2024, then tumbled by -182bps to 0.26% in 2025.
- Its Return on Equity stands at 0.26% for Q3 2025, versus 0.04% for Q2 2025 and 0.12% for Q1 2025.